Trends in use of ezetimibe after the ENHANCE Trial, 2007 Through 2010

JAMA Internal Medicine

Volumn 174, Issue 9, 2014, Pages 1486-1493

  Ross, Joseph S ^a,b,c,d   Frazee, Sharon G ^e   Garavaglia, Susan B ^e   Levin, Rebecca ^e   Novshadian, Haik ^e   Jackevicius, Cynthia A ^f,g   Stettin, Glen ^e   Krumholz, Harlan M ^a,b,c,d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Yale Dept Orthopaedics and Rehab   (United States)

^c YALE UNIVERSITY   (United States)

^d YALE NEW HAVEN HOSPITAL   (United States)

^e Express Scripts   (United States)

^f WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BILE ACID SEQUESTRANT; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; PRESCRIPTION DRUG; SIMVASTATIN; AZETIDINE DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); DRUG USE; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MIDDLE AGED; MONOTHERAPY; PHARMACY BENEFIT MANAGER; POPULATION RESEARCH; PREDICTOR VARIABLE; PRESCRIPTION; RETROSPECTIVE STUDY; SOUTH AMERICA; TIME TO TREATMENT; TREATMENT WITHDRAWAL; TREND STUDY; ADOLESCENT; ATHEROSCLEROSIS; DISEASE COURSE; HEALTH INSURANCE; HYPERCHOLESTEROLEMIA; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; AZETIDINES; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SIMVASTATIN; TREATMENT OUTCOME; UNITED STATES;

EID: 84907015940     PISSN: 21686106     EISSN: 21686114     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.3404     Document Type: Article

References (25)

1. Jackevicius CA, Tu JV, Ross JS, Ko DT, Krumholz HM. Use of ezetimibe in the United States and Canada. N Engl J Med. 2008;358(17):1819-1828.
2. Smith SC Jr, Allen J, Blair SN, et al; AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006; 113(19):2363-2372.
3. Pearson TA, Blair SN, Daniels SR, et al; American Heart Association Science Advisory and Coordinating Committee. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation. 2002;106(3):388-391.
4. Berenson A. Drug has no benefit in trial, makers say. New York Times. January 14, 2008. http://www.nytimes.com/2008/01/14/business/14cnd-drug.html?-r=0. Accessed June 13, 2014.
5. Winslow R, Rubenstein S. Study deals setback to cholesterol drug.Wall Street Journal. January 14, 2008. http://online.wsj.com/news/articles/SB120031937098988415. Accessed June 13, 2014.
6. Kastelein JJ, Akdim F, Stroes ES, et al; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008;358(14):1431-1443.
7. Krumholz HM. Emphasizing the burden of proof: the American College of Cardiology 2008 Expert Panel Comments on the ENHANCE Trial. Circ Cardiovasc Qual Outcomes. 2010;3(6):565-567.
8. Merck and Co. I. 3rd Quarter, 2008: Consolidated Financial Results. Whitehouse Station, NJ:Merck and Co; 2008.
9. Merck and Co. I. 3rd Quarter, 2008: Other Financial Disclosures. Whitehouse Station, NJ: Merck and Co; 2008.
10. Lu L, Krumholz HM, Tu JV, Ross JS, Ko DT, Jackevicius CA. Impact of the ENHANCE trial on the use of ezetimibe in the United States and Canada. Am Heart J. 2014;167(5):683-689.
11. Shrank WH, Choudhry NK, Tong A, et al. Warnings without guidance: patient responses to an FDA warning about ezetimibe. Med Care. 2012; 50(6):479-484.
12. Cadet JV.Merck'sQ4, FY10 net income drops, partly due vorapaxar charges. Cardiovascular Businesswebsite. February 7, 2011. http://www.cardiovascularbusiness.com/topics/coronary -intervention-surgery/mercks-q4-fy10 -net-income-drops-partly-due-vorapaxar-charges. AccessedOctober 4, 2013.
13. US Securities and Exchange Commission. Commission File No. 1-6571: Form 10-Q for Merck & Co., Inc. http://www.sec.gov/Archives/edgar/data/310158/000119312512463586/d400394d10q.htm. Accessed June 13, 2014.
14. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361 (22):2113-2122.
15. Villines TC, Stanek EJ, Devine PJ, et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J AmColl Cardiol. 2010;55(24):2721-2726.
16. West AM, Anderson JD,Meyer CH, et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis. 2011;218(1):156-162.
17. Smith SC Jr, Benjamin EJ, Bonow RO, et al; World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124(22): 2458-2473.
18. US Food and Drug Administration. Early communication about an ongoing data review for ezetimibe/simvastatin (marketed as Vytorin), ezetimibe (marketed as Zetia), and simvastatin (marketed as Zocor). January 25, 2008. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsand Providers/DrugSafetyInformationfor HeathcareProfessionals/ucm070779.htm. Accessed October 4, 2013.
19. Greenland P, Lloyd-Jones D. Critical lessons from the ENHANCE trial. JAMA. 2008;299(8):953-955.
20. American College of CardiologyWeb Site. Statement from the American College of Cardiology Related to the ENHANCE Trial. 2008. http://www.docguide.com/american-college -cardiology-statement-enhance-trial?tsid=5. Accessed June 13, 2014.
21. Brown BG, Taylor AJ. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N Engl J Med. 2008;358(14):1504-1507.
22. Drazen JM, Jarcho JA, Morrissey S, Curfman GD. Cholesterol lowering and ezetimibe. N Engl JMed. 2008;358(14):1507-1508.
23. The Impact of Randomized Clinical Trials on Health Policy and Medical Practice: Background Paper.Washington, DC: US Congress, Office of Technology Assessment; 1983. OTA-BP-H-22.
24. Downing NS, Cheng T, Krumholz HM, Shah ND, Ross JS. Descriptions and interpretations of the ACCORD-lipid trial in the news and biomedical literature: a cross-sectional analysis [published online ahead of printMay 5, 2014]. JAMA Intern Med. doi:10.1001/jamainternmed.2014.1371.
25. Standard Option Generic Incentive Program. Blue Cross Blue Shield Federal Employee Program website. 2012. http://www.fepblue.org/benefitplans/pharmacy-generic-incentive -program.jsp. Accessed October 4, 2013.